(P130) An Exploratory Pilot Study of Perfusion Patterns in Locoregionally Advanced Head and Neck Cancer Using a Novel Analysis Technique of Dynamic Contrast-Enhanced (DCE)-MRI

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

UPR is a novel technique that has been developed in a preclinical tumor model and that is potentially applicable in HNCs. This exploratory study appears consistently to identify subvolumes within the GTV that may have therapeutic implications and that may be promising areas for further research (eg, correlation with hypoxia and clinical outcome).

Jonathan Verma, MD, Radka Stoyanova, PhD, N. Andres Parra, PhD, Kyle Padgett, PhD, Michael Samuels, MD, Nagy Elsayyad, MD; University of Miami Sylvester Comprehensive Cancer Center

PURPOSE: Recently, an unsupervised pattern recognition (UPR) technique was developed by one of the investigators to analyze dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). The technique utilizes non-negative matrix factorization (NMF) and has hitherto not been studied in head and neck cancers (HNCs). This study aims at implementing this technique in HNCs in order to explore its potential value in characterizing perfusion patterns within these tumors. The presence of subvolumes in the HNC that are differentially perfused may have future therapeutic implications with respect to dose painting, intensification, or deintensification of treatment.

METHODS: Eight patients who received definitive chemoradiotherapy for locoregionally advanced HNC were randomly selected. All received 70 Gy/33–35 fractions/6–7 weeks with concurrent cisplatin. As part of the radiotherapy planning, MRI had been obtained for each patient, and DCE sequences were acquired, in addition to the usual T1 and T2 sequences. DCE-MRI datasets with contoured gross target volumes (GTVs) were imported for image analysis into MIM software (MIM Corporation, Cleveland, Ohio). The NMF (non-negative matrix factorization) algorithm was implemented in MIM. There are three characteristic patterns of signal-vs-time curves that UPR identifies within each GTV-namely, Pattern A, which identifies subvolumes with fast contrast uptake and fast washout; Pattern B for subvolumes with delayed uptake and washout; and Pattern C, with slow or no contrast uptake.

RESULTS: The aforementioned three patterns identified corresponding subvolumes in each GTV. The mean GTV volume was 56.8 cc (range: 22–146.6 cc). Subvolumes for each of Patterns A, B, and C averaged 31% ± 3.6%, 30% ± 5.3%, and 39% ± 8.4% of the total GTV, respectively. The standard deviations showed relatively tight dispersion of these values around their respective means, suggesting relative constancy throughout the patients studied. Although no clear geographically consistent relationship between the subvolumes emerged, necrotic regions identified by computed tomography (CT) or MRI were consistently located within Pattern C subvolumes. All three patterns were qualitatively identical to those reported in a previously published preclinical study by our group, wherein Pattern B subvolumes corresponded to regions of tumor hypoxia on 18F-fluoro-misonidazole (MISO) images and radiolabeled pimonidazole histological slices.

CONCLUSION: UPR is a novel technique that has been developed in a preclinical tumor model and that is potentially applicable in HNCs. This exploratory study appears consistently to identify subvolumes within the GTV that may have therapeutic implications and that may be promising areas for further research (eg, correlation with hypoxia and clinical outcome).

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Related Content